KPW
CRNX icon

Kore Private Wealth’s Crinetics Pharmaceuticals CRNX Stock Holding History

Kore Private Wealth’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-415
Closed -$9K – 349
2019
Q1 		$9K Buy
+415
New +$10.2K ﹤0.01% 638

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kore Private Wealth's CRNX Position: Q2 2019 in Review

Kore Private Wealth sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2019, closing a stake of 415 shares — an estimated $9K sold.

Kore Private Wealth first reported a position in CRNX in Q1 2019 and held it in 1 quarter. The position peaked at $9K in Q1 2019. 63 funds tracked by Wall St. Rank hold CRNX as of Q2 2019.

  • Kore Private Wealth reported no remaining Crinetics Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Kore Private Wealth sold 415 Crinetics Pharmaceuticals shares in Q2 2019, an estimated $9K.
  • Kore Private Wealth first reported a position in Crinetics Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Kore Private Wealth's Crinetics Pharmaceuticals position peaked at $9K in Q1 2019.
  • 63 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2019.

Based on Kore Private Wealth's 13F filing for Q2 2019, filed 14 Aug 2019.